Daily Pharma News - 10 October 2026

GST Council Allows Pharma Companies to Claim Input Tax Credit (ITC) on Free Physician Samples and Expired Stock

In a major relief for the Indian pharmaceutical industry, the GST Council has permitted pharma companies to claim input tax credit (ITC) on free physician samples and on goods destroyed upon expiry, effective from FY28. Until now, ITC on goods given away as free samples or written off after expiry was blocked, which meant companies bore the embedded GST cost on promotional and expired inventory without any tax set-off. This decision reverses that burden and is expected to materially improve working capital for formulations manufacturers, vaccine producers and biologics makers, where free-sample distribution and expiry write-offs form a large part of operating costs.

For pharmacy students, this is a live case study in pharmaceutical regulatory and tax law. Free physician samples are supplied to doctors as promotional material, and under GST they count as a "supply" even without consideration — which is exactly why the earlier ITC denial stung. The change links directly to topics in pharmaceutical jurisprudence and management: Section 17(5) of the CGST Act, free-sample economics, and how tax policy shapes marketing and distribution decisions in the Indian pharma industry. Watch how listed Indian companies reflect this benefit in their FY28 margins.

Lupin Gets USFDA Approval for Generic Vitamin K (Phytonadione) Injectable Emulsion

Lupin has received approval from the US Food and Drug Administration (USFDA) for its phytonadione (vitamin K1) injectable emulsion USP 1 mg/0.5 mL, the generic version of the innovator product held by International Medication Systems. The approval establishes bioequivalence to the reference product, and the injectable is indicated for hypoprothrombinemia and vitamin K deficiency — including bleeding disorders caused by anticoagulant therapy such as warfarin overdose or interruption of the vitamin K cycle.

Phytonadione is a textbook example from pharmacology: it promotes hepatic synthesis of clotting factors II, VII, IX and X and proteins C and S. The formulation is also instructive for pharmaceutics students — phytonadione is a fat-soluble vitamin, so an injectable emulsion is needed for parenteral delivery rather than a simple aqueous solution. Lupin's approval is the latest in a long string of US generic wins by Indian companies, reinforcing India's position as the pharmacy of the world for affordable generics and ANDA filings. Students following generic drug approval pathways should note how bioequivalence data, not fresh efficacy trials, carries a 505(j) ANDA application.

Tamil Nadu Drugs Control Orders Hospital Inspections Over Medicine Billing and MRP Violations

The Tamil Nadu Drugs Control department has ordered inspections of hospitals and their attached pharmacies over complaints that inpatients are being billed at or near the printed maximum retail price (MRP) for medicines that the hospitals themselves procure at steep trade discounts. Inspectors will examine billing practices and booking compliance; pricing violations will be prosecuted under the Drugs (Prices Control) Order, 2013 (DPCO 2013).

This is directly relevant to hospital and clinical pharmacy practice in India. Under DPCO 2013, the National Pharmaceutical Pricing Authority (NPPA) fixes ceiling prices for scheduled formulations, and no retailer — including a hospital pharmacy — may sell above the ceiling price. The Tamil Nadu action highlights the long-standing tension between hospital procurement margins and patient billing, a subject pharmacy students encounter in hospital pharmacy and drug store management. It also underlines the enforcement role of state drug control departments, the boots on the ground for the Drugs and Cosmetics Act and DPCO compliance.

China's NMPA Approves Pirtobrutinib (Jaypirca), Noncovalent BTK Inhibitor, for CLL and SLL Across All Treatment Lines

China's National Medical Products Administration (NMPA) has approved pirtobrutinib, marketed as Jaypirca, for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) across all lines of therapy, regardless of prior BTK inhibitor treatment. The approval was supported by the BRUIN CLL-313 and BRUIN CLL-314 trials, which reported an overall response rate (ORR) of 93.3% and a 24-month progression-free survival (PFS) of 93.2%.

Pirtobrutinib is a noncovalent, reversible Bruton's tyrosine kinase (BTK) inhibitor, and its pharmacology matters: first-generation covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib bind irreversibly at the C481 residue, and resistance frequently emerges through BTK C481 mutations. A noncovalent inhibitor retains activity against these resistant clones, which is why an "all lines regardless of prior BTK therapy" label is clinically significant. For Indian pharmacy students, the story connects targeted cancer therapy pharmacology with real-world drug resistance — the same resistance-management logic behind newer-generation TKIs in CML and EGFR-mutant lung cancer. China clearing it broadly also signals how fast NMPA reviews for novel oncology agents have become, a regulatory trend worth tracking against CDSCO timelines.

Russia Registers Givinostat (Gleventra) as First Non-Mutation-Specific Drug for Duchenne Muscular Dystrophy (DMD)

Russia has registered Promomed's Gleventra (givinostat), the first non-mutation-specific therapy for Duchenne muscular dystrophy (DMD) available in the country. Existing DMD options such as ataluren and viltolarsen work only for patients with specific genetic mutations — ataluren for nonsense mutations and viltolarsen as an exon-53-skipping therapy — leaving the majority of DMD patients without a disease-targeted option. Givinostat, a histone deacetylase (HDAC) inhibitor, addresses the downstream muscle pathology rather than a single mutation, making it applicable across the DMD population.

Duchenne muscular dystrophy is a rare, X-linked genetic disorder caused by dystrophin deficiency, and it is a classic example in pharmacology and clinical pharmacy teaching on orphan drugs and targeted therapies. The regulatory angle is equally instructive: rare-disease approvals often rely on accelerated or conditional pathways, and Russia's registration of a domestically produced innovative product reflects the country's push for pharmaceutical sovereignty in high-value biologics and orphan drugs. Students should compare this with India's own rare-disease framework — the National Policy for Rare Diseases and CDSCO's orphan-drug provisions — and consider how mutation-agnostic mechanisms are reshaping rare-disease pipelines.

USFDA Approves Pritelivir, Oral Helicase-Primase Inhibitor, for Resistant Herpes Simplex in Immunocompromised Patients

The USFDA has approved Asahi Kasei's oral pritelivir for persistent herpes simplex virus (HSV) infections in immunocompromised patients who fail current antiviral therapy. In a late-stage trial, 62.7% of patients achieved complete healing at 28 days compared with 34% on the comparator — a meaningful gain in a population with very few options. Pritelivir belongs to a new antiviral class, the helicase-primase inhibitors, which block viral DNA replication at a different step than the nucleoside analogues acyclovir, valacyclovir and famciclovir.

This approval is a pharmacology lesson in drug resistance and new drug classes. Acyclovir resistance in HSV arises mainly through mutations in viral thymidine kinase, the enzyme that activates the drug — a problem concentrated in immunocompromised patients such as transplant recipients and people with advanced HIV, who experience prolonged viral replication. Because pritelivir does not require thymidine-kinase activation, it retains activity against acyclovir-resistant strains. For pharmacy students, the takeaway is twofold: understand resistance mechanisms at the enzyme level, and appreciate why entirely new drug classes — not just "me-too" analogues — are needed to break resistance cycles in antiviral therapy.

FDA Approves Teva's Weltruza — First Once-Monthly Subcutaneous Olanzapine Injectable for Schizophrenia

The USFDA has approved Teva's Weltruza, the first once-monthly subcutaneous injectable formulation of olanzapine for adults with schizophrenia, based on the phase 3 SOLARIS trial. The long-acting injectable requires no loading doses and no oral supplementation during initiation — a practical advantage over several existing long-acting antipsychotics that need bridging oral therapy or complex initiation regimens.

Olanzapine is a second-generation (atypical) antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors, and it is a mainstay in schizophrenia pharmacotherapy — a core B.Pharm and Pharm.D topic. The clinical problem this product solves is adherence: schizophrenia relapse is strongly linked to missed oral doses, and long-acting injectables (LAIs) like aripiprazole and risperidone microspheres already exist, but a once-monthly subcutaneous olanzapine with simple initiation fills a genuine gap. Students of pharmaceutics should note the formulation achievement here — delivering a poorly soluble antipsychotic as a stable monthly subcutaneous depot — while clinical pharmacy students should weigh the benefit against olanzapine's well-known metabolic side effects (weight gain, dyslipidaemia, hyperglycaemia), which remain relevant regardless of dosage form.

Conclusion

Today's news reads like a syllabus in motion. India led with policy and industry — the GST Council's ITC relief for pharma and Lupin's USFDA win for generic phytonadione — while Tamil Nadu's hospital billing crackdown reminded us that drug pricing law is enforced, not just written. Globally, the theme was innovation against resistance and unmet need: China's NMPA clearing pirtobrutinib across all CLL/SLL lines, Russia registering the first mutation-agnostic DMD therapy in givinostat, the FDA approving pritelivir for drug-resistant herpes, and the first monthly subcutaneous olanzapine for schizophrenia.

For pharmacy students, the connective tissue is clear. Pharmacology explains why noncovalent BTK inhibition beats resistance and why helicase-primase inhibition works where acyclovir fails. Pharmaceutics explains injectable emulsions and monthly depots. Regulatory affairs and jurisprudence explain ANDA bioequivalence, DPCO enforcement and GST input tax credit. Follow the science, but always read the regulation beside it — that is where classroom knowledge becomes professional judgment.

References

← All daily news